BRPI0818536A2 - Linhagem celular cho-k1 - Google Patents

Linhagem celular cho-k1

Info

Publication number
BRPI0818536A2
BRPI0818536A2 BRPI0818536-0A2A BRPI0818536A BRPI0818536A2 BR PI0818536 A2 BRPI0818536 A2 BR PI0818536A2 BR PI0818536 A BRPI0818536 A BR PI0818536A BR PI0818536 A2 BRPI0818536 A2 BR PI0818536A2
Authority
BR
Brazil
Prior art keywords
cho
cell line
cell
line
Prior art date
Application number
BRPI0818536-0A2A
Other languages
English (en)
Inventor
Erhard Kopetzki
Ursula Schwarz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818536(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0818536A2 publication Critical patent/BRPI0818536A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BRPI0818536-0A2A 2007-10-12 2008-10-13 Linhagem celular cho-k1 BRPI0818536A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07019999 2007-10-12
PCT/EP2008/008636 WO2009047007A1 (en) 2007-10-12 2008-10-13 Cho-k1 cell line

Publications (1)

Publication Number Publication Date
BRPI0818536A2 true BRPI0818536A2 (pt) 2014-10-14

Family

ID=39204855

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0818165A BRPI0818165B8 (pt) 2007-10-12 2008-10-09 método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
BRPI0818536-0A2A BRPI0818536A2 (pt) 2007-10-12 2008-10-13 Linhagem celular cho-k1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0818165A BRPI0818165B8 (pt) 2007-10-12 2008-10-09 método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura

Country Status (20)

Country Link
US (5) US8771988B2 (pt)
EP (4) EP2592147A1 (pt)
JP (2) JP5642549B2 (pt)
KR (2) KR101280704B1 (pt)
CN (2) CN101815786A (pt)
AU (2) AU2008309934B2 (pt)
BR (2) BRPI0818165B8 (pt)
CA (2) CA2701646C (pt)
DK (1) DK2592148T3 (pt)
ES (1) ES2695999T3 (pt)
HR (1) HRP20181833T1 (pt)
HU (1) HUE039950T2 (pt)
IL (2) IL203902A0 (pt)
LT (1) LT2592148T (pt)
MX (3) MX338036B (pt)
PL (1) PL2592148T3 (pt)
PT (1) PT2592148T (pt)
SI (1) SI2592148T1 (pt)
TR (1) TR201816045T4 (pt)
WO (2) WO2009046978A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803484A (zh) 2009-06-11 2012-11-28 大学共同利用机关法人情报·系统研究机构 生产蛋白质的方法
DK3241435T3 (da) * 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
WO2011057360A1 (en) * 2009-11-16 2011-05-19 Acyte Biotech Pty Ltd Recombinant antibody vector
US9096879B2 (en) * 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
CN102858953B (zh) 2010-04-26 2015-09-09 诺瓦提斯公司 改进的细胞培养基
US9068198B2 (en) 2010-09-15 2015-06-30 Medimmune Limited Chinese hamster ovary cell line
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN107881196A (zh) 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2674495A1 (en) * 2012-06-14 2013-12-18 Sanofi CHO expression system
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
SG10201809452RA (en) 2013-03-15 2018-11-29 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
LT3074424T (lt) 2013-11-27 2025-05-26 Zymeworks Bc Inc. Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
DK3122869T3 (da) 2014-03-24 2019-09-09 Biogen Ma Inc Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
PL3140392T3 (pl) * 2014-05-06 2023-11-27 F. Hoffmann-La Roche Ag Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
AU2015290571B2 (en) * 2014-07-16 2021-03-04 Heartseed Inc. New undifferentiated stem cell removal and myocardial purification and refinement culture medium
US10774353B2 (en) * 2015-04-27 2020-09-15 Momenta Pharmaceuticals, Inc. Methods of manufacturing therapeutic proteins
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
GB201718088D0 (en) * 2017-11-01 2017-12-13 Autolus Ltd Vectors
CN111019881B (zh) * 2019-11-21 2020-10-09 中山康天晟合生物技术有限公司 一种适应高渗透压、高铵离子、高乳酸生长环境的细胞
MX2022013173A (es) 2020-04-24 2022-11-30 Hoffmann La Roche Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN112920995A (zh) * 2021-03-31 2021-06-08 赵峻岭 一种间充质干细胞培养血清加油包及其应用
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CN115521919B (zh) * 2022-11-04 2023-04-11 广州誉衡生物科技有限公司 一种调节pd-1抗体和lag-3抗体酸性电荷异构体的cho细胞培养方法
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
WO2026120069A1 (en) 2024-12-05 2026-06-11 H. Lundbeck A/S Humanized anti-pacap antibody and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912038A (en) 1984-12-11 1990-03-27 California Biotechnology Inc. Recombinant DNA sequence encoding alveolar surfactant protein
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
EP0368926A4 (en) 1987-07-16 1991-11-27 Codon Transfected cells containing plasmids having genes oriented in opposing directions and methods of obtaining the same
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
EP0319206A3 (en) 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gene amplification
WO1989010959A1 (en) 1988-05-06 1989-11-16 Codon Supertransformants for high expression rates in eukaryotic cells
DD287531A5 (de) 1988-06-16 1991-02-28 Akademie Der Wissenschaften,De Verfahren zur herstellung von humanem wachstumshormon (sth) in tierischen zellen
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
JP2859679B2 (ja) * 1990-03-01 1999-02-17 協和醗酵工業株式会社 新規細胞株
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
EP0569678A3 (de) 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
WO1994025067A1 (en) 1993-05-04 1994-11-10 Cytel Corporation Antibodies to p-selectin and their uses
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
WO1995017513A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Retransformation of filamentous fungi
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
WO1997008342A1 (en) 1995-08-30 1997-03-06 Gentest Corporation Cytochrome p450 reporter gene
EP2221361A3 (en) * 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CA2310987A1 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
CA2324518A1 (en) * 1998-03-18 1999-09-23 Pharmacopeia, Inc. Eukaryotic cells stably expressing genes from multiple transfected episomes
BR9905867A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
TW570977B (en) 1998-12-07 2004-01-11 Li-Wei Hsu An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
DE19920712A1 (de) 1999-05-05 2000-11-09 Rhein Biotech Proz & Prod Gmbh Verfahren zum Herstellen eines rekombinanten Proteines
NZ529329A (en) * 1999-08-25 2005-06-24 Immunex Corp Compositions and methods for improved cell culture
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
DE10036491A1 (de) * 2000-07-25 2002-02-07 Roche Diagnostics Gmbh Expression von Alkalischer Phosphatase in Hefe
HRP20040477A2 (en) 2001-11-28 2005-06-30 Sandoz Gmbh Method for producing a recombinant polypeptide
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
EP1488234A4 (en) 2002-03-05 2006-05-24 Vitra Bioscience Inc TRANSFECTION OF MULTIPLEXED CELLS USING CODED MEDIA
DE10213201A1 (de) 2002-03-25 2003-10-16 Roche Diagnostics Gmbh Erzeugung von schwach aktiven oder inaktiven Mutanten von Alkalischer Phosphatase und deren Expression in Hefe
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
TWI306862B (en) * 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
US20070218062A1 (en) 2006-03-16 2007-09-20 Genentech, Inc. Methods of treating lupus using CD4 antibodies
KR101263294B1 (ko) * 2006-03-30 2013-06-04 글락소 그룹 리미티드 아밀로이드­베타 펩티드에 대한 항체
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos

Also Published As

Publication number Publication date
US20140335609A1 (en) 2014-11-13
JP2011500009A (ja) 2011-01-06
WO2009047007A1 (en) 2009-04-16
WO2009046978A1 (en) 2009-04-16
IL203900A (en) 2014-08-31
US20100249379A1 (en) 2010-09-30
CA2701677A1 (en) 2009-04-16
US8771988B2 (en) 2014-07-08
IL203902A0 (en) 2011-07-31
KR101280704B1 (ko) 2013-07-01
JP2010540583A (ja) 2010-12-24
KR20100059967A (ko) 2010-06-04
CA2701646A1 (en) 2009-04-16
JP5642549B2 (ja) 2014-12-17
EP2592148B1 (en) 2018-09-12
HUE039950T2 (hu) 2019-02-28
CN101815786A (zh) 2010-08-25
AU2008309934A1 (en) 2009-04-16
EP2592148A1 (en) 2013-05-15
MX2010003622A (es) 2010-04-14
AU2008309934B2 (en) 2014-03-06
TR201816045T4 (tr) 2018-11-21
KR20100059969A (ko) 2010-06-04
US20100221781A1 (en) 2010-09-02
US20190233842A1 (en) 2019-08-01
EP2207881A1 (en) 2010-07-21
SI2592148T1 (sl) 2018-12-31
US20170166923A1 (en) 2017-06-15
ES2695999T3 (es) 2019-01-11
BRPI0818165B1 (pt) 2020-10-27
IL203900A0 (en) 2011-07-31
DK2592148T3 (en) 2018-12-10
EP2592147A1 (en) 2013-05-15
CA2701646C (en) 2019-02-26
LT2592148T (lt) 2018-12-10
CN101821394A (zh) 2010-09-01
HRP20181833T1 (hr) 2019-01-11
PL2592148T3 (pl) 2019-01-31
MX2010003620A (es) 2010-04-14
EP2207882A1 (en) 2010-07-21
AU2008309881A1 (en) 2009-04-16
BRPI0818165B8 (pt) 2021-05-25
PT2592148T (pt) 2018-11-12
US9428766B2 (en) 2016-08-30
MX338036B (es) 2016-03-31
BRPI0818165A2 (pt) 2014-10-14

Similar Documents

Publication Publication Date Title
CL2007002310S1 (es) Telefono celular.
BRPI0716762A2 (pt) melhorias da cultura celular
IL203902A0 (en) Cho-k1 cell line
PL2634242T3 (pl) Ulepszony sposób hodowli komórek
EP2005504A4 (en) ELECTROLYTE
BRPI0816956A2 (pt) Célula de combustível
EP2095430A4 (en) SOLAR CELL
EP2211411A4 (en) Fuel cell system
BRPI0908741A2 (pt) Monofone de telefone celular
DE112008000649B8 (de) Brennstoffzellensystem
DE112008000870B8 (de) Brennstoffzellensystem
DE602008000048D1 (de) Brennstoffzelle
DE112007001371B8 (de) Brennstoffzelle
DE112007002407B8 (de) Brennstoffzelle
BRPI0714209A2 (pt) Induzidor de morte celular
DE602008000154D1 (de) Brennstoffzellensystem
DE112008000393B8 (de) Brennstoffzellensystem
DE112008003478B8 (de) Brennstoffzellensystem
DK2027150T3 (da) Allo-begrænsede peptid-specifikke t-celler
DE602008003477D1 (de) Brennstoffzellensystem
BRPI0814572A2 (pt) Célula de lítio
DE602008002852D1 (de) Brennstoffzellsystem
DE112008003372B8 (de) Brennstoffzellensystem
HUE038157T2 (hu) Geoszõnyeg
BRPI0813726A2 (pt) Célula de lítio

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]